EXICURE, INC. 8-K

What Happened

• EXICURE, Inc. (filed 8-K on January 22, 2026) announced it achieved the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc. The milestone was the completion of EXICURE’s Phase 2 clinical trial of its CXCR4 inhibitor Burixafor (GPC‑100), documented by formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.
• Under the Agreement, EXICURE must make a milestone payment of $1,000,000 to GPCR within 30 days of achieving the milestone, and the company said it intends to make that payment. Completion of the milestone also triggers an updated future sublicensing income‑sharing ratio under the Agreement.

Key Details

• Filing date: Form 8-K filed January 22, 2026 (milestone achieved January 16, 2026 upon CSR submission to FDA).
• Trial ID and asset: Phase 2 clinical trial NCT05561751 for Burixafor (GPC‑100), a small‑molecule CXCR4 inhibitor.
• Payment obligation: $1,000,000 due to GPCR Therapeutics Inc. within 30 days of milestone achievement.
• Commercial terms: Milestone completion adjusts future sublicensing income‑sharing ratio, increasing EXICURE’s participation in potential downstream sublicensing revenue.

Why It Matters

• This is a concrete operational milestone showing progress in EXICURE’s clinical program for Burixafor and moves the collaboration with GPCR forward.
• There is a near‑term cash outflow of $1.0 million required within 30 days, which is a known, material contractual obligation.
• Triggering an increased sublicensing income‑sharing ratio could boost EXICURE’s share of future partnership or sublicensing revenues if and when such deals occur, but the filing does not announce any new revenue or sublicensing transactions now.